Therapeutic bispecific antibodies cross the blood-brain barrier in nonhuman primates

A Highly Efficient Recombineering-Based Method for Generating Conditional Knockout MutationsPreprint

Liu, P., Jenkins, N. A., & Copeland, N. G. (2003) · Genome Research · doi:10.1101/gr.749203 · Cited by 1,013 · see citing works

‘Knobs-into-holes’ engineering of antibody C H 3 domains for heavy chain heterodimerization

Ridgway, J. B., Presta, L. G., & Carter, P. M. (1996) · Protein Engineering Design and Selection · doi:10.1093/protein/9.7.617 · Cited by 816 · see citing works

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · see citing works

Targeting the β secretase BACE1 for Alzheimer's disease therapy

Yan, R., & Vassar, R. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70276-x · Cited by 628 · see citing works

Increased Brain Penetration and Potency of a Therapeutic Antibody Using a Monovalent Molecular Shuttle

Niewoehner, J., Bohrmann, B., Collin, L., Urich, E., Sade, H., Maier, P., Rueger, P., Stracke, J. O., Lau, W., Tissot, A. C., et al. (2014) · Neuron · doi:10.1016/j.neuron.2013.10.061 · Cited by 622 · see citing works

Blood–Brain Barrier Transport of Therapeutics via Receptor-Mediation

Jones, A. R., & Shusta, E. V. (2007) · Pharmaceutical Research · doi:10.1007/s11095-007-9379-0 · Cited by 549 · see citing works

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 350 · see citing works

A Therapeutic Antibody Targeting BACE1 Inhibits Amyloid-β Production in Vivo

Atwal, J. K., Chen, Y., Chiu, C., Mortensen, D. L., Meilandt, W. J., Liu, Y., Heise, C. E., Hoyte, K., Luk, W., Lu, Y., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002254 · Cited by 274 · see citing works

Addressing Safety Liabilities of TfR Bispecific Antibodies That Cross the Blood-Brain Barrier

Couch, J. A., Yu, Y. J., Zhang, Y., Tarrant, J. M., Fuji, R. N., Meilandt, W. J., Solanoy, H. O., Tong, R. K., Hoyte, K., Luk, W., et al. (2013) · Science Translational Medicine · doi:10.1126/scitranslmed.3005338 · Cited by 270 · see citing works

Developing Therapeutic Antibodies for Neurodegenerative Disease

Yu, Y. J., & Watts, R. J. (2013) · Neurotherapeutics · doi:10.1007/s13311-013-0187-4 · Cited by 227 · see citing works

Zfp423 Is Required for Normal Cerebellar Development

Warming, S., Rachel, R. A., Jenkins, N. A., & Copeland, N. G. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.02255-05 · Cited by 80 · see citing works

Bispecific antibodies for delivery into the brain

Watts, R. J., & Dennis, M. S. (2013) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2013.03.023 · Cited by 74 · see citing works

Macromolecular drug transport into the brain using targeted therapy

Lichota, J., Skjørringe, T., Thomsen, L. B., & Moos, T. (2009) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2009.06544.x · Cited by 74 · see citing works

A Therapeutic Antibody Targeting Bace1 Inhibits Amyloid-beta Production in Vivo

Atwal, J. K., Chen, Y., Chiu, C. W., Mortensen, D. L., Meilandt, W. J., liu, Y., Heise, C., Hoyte, K., Luk, W., Lu, Y., et al. (2013) · OSTI OAI (U.S. Department of Energy Office of Scientific and Technical Information) · Cited by 56 · see citing works

Inhibition of β-Secretase in Vivo via Antibody Binding to Unique Loops (D and F) of BACE1*

Zhou, L., Chávez-Gutiérrez, L., Bockstael, K., Sannerud, R., Annaert, W., May, P., Karran, E., & de Strooper, B. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.194860 · Cited by 52 · see citing works

Breaching the Blood-Brain Barrier for Drug Delivery

Bell, R. D., & Ehlers, M. (2014) · Neuron · doi:10.1016/j.neuron.2013.12.023 · Cited by 47 · see citing works

Cerebrospinal Fluid Amyloid-β (Aβ) as an Effect Biomarker for Brain Aβ Lowering Verified by Quantitative Preclinical Analyses

Lu, Y.-S., Riddell, D., Hajós-Korcsok, É., Bales, K., Wood, K. M., Nolan, C., Robshaw, A., Zhang, L.-M., Leung, L. Y., Becker, S. L., et al. (2012) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.112.192625 · Cited by 37 · see citing works

Blood–brain barrier breakdown in Alzheimer disease and other neurodegenerative disorders

Sweeney, M. D., Sagare, A. P., & Zlokovic, B. V. (2018) · Nature Reviews Neurology · doi:10.1038/nrneurol.2017.188 · Cited by 3,076 · see citing works

Blood-Brain Barrier: From Physiology to Disease and Back

Sweeney, M. D., Zhao, Z., Montagne, A., Nelson, A. R., & Zlokovic, B. V. (2019) · Physiological Reviews · doi:10.1152/physrev.00050.2017 · Cited by 2,294 · see citing works

Bispecific antibodies: a mechanistic review of the pipeline

Labrijn, A. F., Janmaat, M. L., Reichert, J. M., & Parren, P. W. H. I. (2019) · Nature Reviews Drug Discovery · doi:10.1038/s41573-019-0028-1 · Cited by 1,303 · see citing works

Strategies for delivering therapeutics across the blood–brain barrier

Terstappen, G. C., Meyer, A. H., Bell, R. D., & Zhang, W. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00139-y · Cited by 1,138 · see citing works

In vitro models of the blood–brain barrier: An overview of commonly used brain endothelial cell culture models and guidelines for their use

Helms, H. C., Abbott, N. J., Burek, M., Cecchelli, R., Couraud, P.-O., Deli, M. A., Förster, C., Galla, H. J., Romero, I. A., Shusta, E. V., et al. (2016) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x16630991 · Cited by 843 · see citing works

Next generation antibody drugs: pursuit of the 'high-hanging fruit'

Carter, P. J., & Lazar, G. A. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.227 · Cited by 760 · see citing works

Antibody Structure and Function: The Basis for Engineering Therapeutics

Chiu, M. L., Goulet, D. R., Teplyakov, A., & Gilliland, G. L. (2019) · Antibodies · doi:10.3390/antib8040055 · Cited by 646 · see citing works

Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier function and shuttling of drugs and antibodies

Park, T., Mustafaoğlu, N., Herland, A., Hasselkus, R., Mannix, R. J., Fitzgerald, E. A., Prantil‐Baun, R., Watters, A. L., Henry, O., Benz, M. A., et al. (2019) · Nature Communications · doi:10.1038/s41467-019-10588-0 · Cited by 600 · see citing works

The vascular basement membrane in the healthy and pathological brain

Thomsen, M. S., Routhe, L. G., & Moos, T. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17722436 · Cited by 485 · see citing works

Blood–brain barrier shuttle peptides: an emerging paradigm for brain delivery

Oller‐Salvia, B., Sánchez‐Navarro, M., Giralt, E., & Teixidò, M. (2016) · Chemical Society Reviews · doi:10.1039/c6cs00076b · Cited by 443 · see citing works

BACE1 inhibitor drugs in clinical trials for Alzheimer’s disease

Vassar, R. J. (2014) · Alzheimer s Research & Therapy · doi:10.1186/s13195-014-0089-7 · Cited by 413 · see citing works

Ferritin Nanocarrier Traverses the Blood Brain Barrier and Kills Glioma

Fan, K., Jia, X., Zhou, M., Wang, K., Conde, J., He, J., Tian, J., & Yan, X. (2018) · ACS Nano · doi:10.1021/acsnano.7b06969 · Cited by 398 · see citing works

Targeting the transferrin receptor for brain drug delivery

Johnsen, K. B., Burkhart, A., Thomsen, L. B., Andresen, T. L., & Moos, T. (2019) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2019.101665 · Cited by 372 · see citing works

Brain delivery of therapeutic proteins using an Fc fragment blood-brain barrier transport vehicle in mice and monkeys

Kariolis, M. S., Wells, R. C., Getz, J. A., Kwan, W., Mahon, C. S., Tong, R. K., Kim, D. J., Srivastava, A., Bédard, C., Henne, K. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1359 · Cited by 356 · see citing works

Targeting cellular pathways in glioblastoma multiforme

Pearson, J. R. D., & Regad, T. (2017) · Signal Transduction and Targeted Therapy · doi:10.1038/sigtrans.2017.40 · Cited by 343 · see citing works

Effector-attenuating Substitutions That Maintain Antibody Stability and Reduce Toxicity in Mice

Lo, M., Kim, H. S., Tong, R. K., Bainbridge, T. W., Vernes, J.-M., Zhang, Y., Lin, Y. L., Chung, S., Dennis, M. S., Zuchero, Y. J. Y., et al. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.m116.767749 · Cited by 312 · see citing works

The Translational Significance of the Neurovascular Unit

McConnell, H. L., Kersch, C. N., Woltjer, R. L., & Neuwelt, E. A. (2017) · Journal of Biological Chemistry · doi:10.1074/jbc.r116.760215 · Cited by 314 · see citing works

Bispecific Antibodies: From Research to Clinical Application

Ma, J., Mo, Y., Tang, M., Shen, J., Qi, Y., Zhao, W., Huang, Y., Xu, Y., & Qian, C. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.626616 · Cited by 310 · see citing works

Tutorial on monoclonal antibody pharmacokinetics and its considerations in early development

Ovacik, M., & Lin, K. (2018) · Clinical and Translational Science · doi:10.1111/cts.12567 · Cited by 299 · see citing works

Bispecific antibodies: design, therapy, perspectives

Sedykh, S. E., Prinz, V. Y., Buneva, V. N., & Nevinsky, G. A. (2018) · Drug Design Development and Therapy · doi:10.2147/dddt.s151282 · Cited by 292 · see citing works

Discovery of Novel Blood-Brain Barrier Targets to Enhance Brain Uptake of Therapeutic Antibodies

Zuchero, Y. J. Y., Chen, X., Bien‐Ly, N., Bumbaca, D., Tong, R. K., Gao, X., Zhang, S., Hoyte, K., Luk, W., Huntley, M. A., et al. (2015) · Neuron · doi:10.1016/j.neuron.2015.11.024 · Cited by 283 · see citing works

Tau-based therapies in neurodegeneration: opportunities and challenges

Li, C., & Götz, J. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.155 · Cited by 272 · see citing works

Current progress in innovative engineered antibodies

Strohl, W. R. (2017) · Protein & Cell · doi:10.1007/s13238-017-0457-8 · Cited by 282 · see citing works

Exploiting Nanobodies’ Singular Traits

Ingram, J. R., Schmidt, F. I., & Ploegh, H. L. (2018) · Annual Review of Immunology · doi:10.1146/annurev-immunol-042617-053327 · Cited by 254 · see citing works

Smart drug delivery systems for precise cancer therapy

Wang, X., Li, C., Wang, Y., Chen, H., Zhang, X., Luo, C., Zhou, W., Li, L., Teng, L., Yu, H., et al. (2022) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2022.08.013 · Cited by 238 · see citing works

Antibody-based PET imaging of amyloid beta in mouse models of Alzheimer’s disease

Sehlin, D., Fang, X. T., Cato, L., Antoni, G., Lannfelt, L., & Syvänen, S. (2016) · Nature Communications · doi:10.1038/ncomms10759 · Cited by 223 · see citing works

Peripheral immune system in aging and Alzheimer’s disease

Cao, W., & Zheng, H. (2018) · Molecular Neurodegeneration · doi:10.1186/s13024-018-0284-2 · Cited by 214 · see citing works

Brain penetrating peptides and peptide–drug conjugates to overcome the blood–brain barrier and target CNS diseases

Zhou, X., Smith, Q. R., & Liu, X. (2021) · Wiley Interdisciplinary Reviews Nanomedicine and Nanobiotechnology · doi:10.1002/wnan.1695 · Cited by 218 · see citing works

A Historical Review of Brain Drug Delivery

Pardridge, W. M. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061283 · Cited by 219 · see citing works

Intracellular transport and regulation of transcytosis across the blood–brain barrier

Villaseñor, R., Lampe, J., Schwaninger, M., & Collin, L. (2018) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-018-2982-x · Cited by 213 · see citing works

Brain delivery and activity of a lysosomal enzyme using a blood–brain barrier transport vehicle in mice

Ullman, J. C., Arguello, A., Getz, J. A., Bhalla, A., Mahon, C. S., Wang, J., Giese, T., Bedard, C., Kim, D. J., Blumenfeld, J. R., et al. (2020) · Science Translational Medicine · doi:10.1126/scitranslmed.aay1163 · Cited by 205 · see citing works

Differential expression of receptors mediating receptor-mediated transcytosis (RMT) in brain microvessels, brain parenchyma and peripheral tissues of the mouse and the human

Zhang, W., Liu, Q. Y., Haqqani, A. S., Leclerc, S., Liu, Z., Fauteux, F., Baumann, E., Delaney, C. E., Ly, D., Star, A. T., et al. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00209-0 · Cited by 200 · see citing works

Development of Novel Therapeutics Targeting the Blood–Brain Barrier: From Barrier to Carrier

Li, J., Zheng, M., Shimoni, O., Banks, W. A., Bush, A. I., Gamble, J. R., & Shi, B. (2021) · Advanced Science · doi:10.1002/advs.202101090 · Cited by 202 · see citing works

An AAV capsid reprogrammed to bind human transferrin receptor mediates brain-wide gene delivery

Huang, Q., Chan, K. Y., Wu, J. H., Botticello-Romero, N. R., Zheng, Q., Lou, S., Keyes, C., Svanbergsson, A., Johnston, J., Mills, A., et al. (2024) · Science · doi:10.1126/science.adm8386 · Cited by 200 · see citing works

A Blood-Brain-Barrier-Penetrating Anti-human Transferrin Receptor Antibody Fusion Protein for Neuronopathic Mucopolysaccharidosis II

Sonoda, H., Morimoto, H., Yoden, E., Koshimura, Y., Kinoshita, M., Golovina, G., Takagi, H., Yamamoto, R., Minami, K., Mizoguchi, A., et al. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.02.032 · Cited by 198 · see citing works

Treatment of Alzheimer’s Disease and Blood–Brain Barrier Drug Delivery

Pardridge, W. M. (2020) · Pharmaceuticals · doi:10.3390/ph13110394 · Cited by 193 · see citing works

Minimally Invasive and Regenerative Therapeutics

Ashammakhi, N. A., Ahadian, S., Darabi, M. A., Tahchi, M. R. E., Lee, J., Suthiwanich, K., Sheikhi, A., Dokmeci, M. R., Öklü, R., & Khademhosseini, A. (2018) · Advanced Materials · doi:10.1002/adma.201804041 · Cited by 192 · see citing works

A D ‐Peptide Ligand of Nicotine Acetylcholine Receptors for Brain‐Targeted Drug Delivery

Wei, X., Zhan, C., Shen, Q., Fu, W., Xie, C., Gao, J., Peng, C., Zheng, P., & Lu, W. (2015) · Angewandte Chemie International Edition · doi:10.1002/anie.201411226 · Cited by 181 · see citing works

Delivery of the Brainshuttle™ amyloid-beta antibody fusion trontinemab to non-human primate brain and projected efficacious dose regimens in humans

Grimm, H. P., Schumacher, V. L., Schäfer, M. K.-H., Imhof-Jung, S., Freskgård, P., Brady, K., Hofmann, C., Rüger, P., Schlothauer, T., Göpfert, U., et al. (2023) · mAbs · doi:10.1080/19420862.2023.2261509 · Cited by 173 · see citing works

Therapeutic approaches targeting Apolipoprotein E function in Alzheimer’s disease

Williams, T., Borchelt, D., & Chakrabarty, P. (2020) · Molecular Neurodegeneration · doi:10.1186/s13024-020-0358-9 · Cited by 166 · see citing works

Leveraging Physiology for Precision Drug Delivery

Sun, W., Hu, Q., Ji, W., Wright, G., & Gu, Z. (2017) · Physiological Reviews · doi:10.1152/physrev.00015.2016 · Cited by 169 · see citing works

Bispecific antibody drug conjugates: Making 1+1>2

Gu, Y., Wang, Z., & Wang, Y. (2024) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2024.01.009 · Cited by 168 · see citing works

Antibody affinity and valency impact brain uptake of transferrin receptor-targeted gold nanoparticles

Johnsen, K. B., Bak, M., Kempen, P. J., Melander, F., Burkhart, A., Thomsen, M. S., Nielsen, M. S., Moos, T., & Andresen, T. L. (2018) · Theranostics · doi:10.7150/thno.25228 · Cited by 157 · see citing works

The Dawn of a New Era: Targeting the “Undruggables” with Antibody-Based Therapeutics

Qian, L., Lin, X., Gao, X., Khan, R. U., Liao, J., Du, S., Ge, J., Zeng, S., & Yao, S. Q. (2023) · Chemical Reviews · doi:10.1021/acs.chemrev.2c00915 · Cited by 156 · see citing works

Receptor-mediated transcytosis for brain delivery of therapeutics: receptor classes and criteria

Haqqani, A. S., Bélanger, K., & Stanimirovic, D. B. (2024) · Frontiers in Drug Delivery · doi:10.3389/fddev.2024.1360302 · Cited by 153 · see citing works

Enhanced glutathione PEGylated liposomal brain delivery of an anti-amyloid single domain antibody fragment in a mouse model for Alzheimer's disease

Rotman, M., Welling, M. M., Bunschoten, A., de Backer, M. E., Rip, J., Nabuurs, R. J. A., Gaillard, P. J., van Buchem, M. A., van der Maarel, S. M., & van der Weerd, L. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.02.012 · Cited by 152 · see citing works

Iduronate-2-Sulfatase with Anti-human Transferrin Receptor Antibody for Neuropathic Mucopolysaccharidosis II: A Phase 1/2 Trial

Okuyama, T., Eto, Y., Sakai, N., Minami, K., Yamamoto, T., Sonoda, H., Yamaoka, M., Tachibana, K., Hirato, T., & Sato, Y. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.12.005 · Cited by 151 · see citing works

Strategies for non-viral vectors targeting organs beyond the liver

Kim, J., Eygeris, Y., Ryals, R. C., Jozić, A., & Sahay, G. (2023) · Nature Nanotechnology · doi:10.1038/s41565-023-01563-4 · Cited by 154 · see citing works

Brain-on-a-chip: Recent advances in design and techniques for microfluidic models of the brain in health and disease

Amirifar, L., Shamloo, A., Nasiri, R., de Barros, N. R., Wang, Z. Z., Unluturk, B. D., Libanori, A., Ievglevskyi, O., Di̇ltemi̇z, S. E., Sances, S., et al. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121531 · Cited by 148 · see citing works

A tetravalent TREM2 agonistic antibody reduced amyloid pathology in a mouse model of Alzheimer’s disease

Zhao, P., Xu, Y., Jiang, L., Fan, X., Li, L., Li, X., Arase, H., Zhao, Y., Cao, W., Zheng, H., et al. (2022) · Science Translational Medicine · doi:10.1126/scitranslmed.abq0095 · Cited by 141 · see citing works

Delivery of Biologics Across the Blood–Brain Barrier with Molecular Trojan Horse Technology

Pardridge, W. M. (2017) · BioDrugs · doi:10.1007/s40259-017-0248-z · Cited by 152 · see citing works

Systemic Delivery of Monoclonal Antibodies to the Central Nervous System for Brain Tumor Therapy

Han, L., Liu, C., Qi, H., Zhou, J., Wen, J., Wu, D., Xu, D., Qin, M., Ren, J., Wang, Q., et al. (2019) · Advanced Materials · doi:10.1002/adma.201805697 · Cited by 145 · see citing works

Adenosine receptor signaling: a key to opening the blood–brain door

Bynoe, M. S., Viret, C., Yan, A., & Kim, D.-G. (2015) · Fluids and Barriers of the CNS · doi:10.1186/s12987-015-0017-7 · Cited by 139 · see citing works

Revisiting nanoparticle technology for blood–brain barrier transport: Unfolding at the endothelial gate improves the fate of transferrin receptor-targeted liposomes

Johnsen, K. B., & Moos, T. (2015) · Journal of Controlled Release · doi:10.1016/j.jconrel.2015.11.032 · Cited by 132 · see citing works

The therapeutic and diagnostic potential of the prostate specific membrane antigen/glutamate carboxypeptidase II (PSMA/GCPII) in cancer and neurological disease

Evans, J. C., Malhotra, M., Cryan, J. F., & O’Driscoll, C. M. (2016) · British Journal of Pharmacology · doi:10.1111/bph.13576 · Cited by 123 · see citing works

Excess cerebral TNF causing glutamate excitotoxicity rationalizes treatment of neurodegenerative diseases and neurogenic pain by anti-TNF agents

Clark, I. A., & Vissel, B. (2016) · Journal of Neuroinflammation · doi:10.1186/s12974-016-0708-2 · Cited by 123 · see citing works

Smart Strategies for Therapeutic Agent Delivery into Brain across the Blood-Brain Barrier Using Receptor-Mediated Transcytosis

Tashima, T. (2020) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.c19-00854 · Cited by 120 · see citing works

Immune Escape in Glioblastoma Multiforme and the Adaptation of Immunotherapies for Treatment

Pearson, J. R. D., Cuzzubbo, S., McArthur, S., Durrant, L. G., Adhikaree, J., Tinsley, C. J., Pockley, A. G., & McArdle, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.582106 · Cited by 118 · see citing works

Blood-brain barrier dysfunction and Alzheimer’s disease: associations, pathogenic mechanisms, and therapeutic potential

Chen, Y., He, Y., Han, J., Wei, W., & Chen, F. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1258640 · Cited by 116 · see citing works

Antibody semorinemab reduces tau pathology in a transgenic mouse model and engages tau in patients with Alzheimer’s disease

Ayalon, G., Lee, S.-H., Adolfsson, O., Foo‐Atkins, C., Atwal, J. K., Blendstrup, M., Booler, H. S., Bravo, J., Brendza, R. P., Brunstein, F., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.abb2639 · Cited by 108 · see citing works

An MMP-9 exclusive neutralizing antibody attenuates blood-brain barrier breakdown in mice with stroke and reduces stroke patient-derived MMP-9 activity

Ji, Y., Gao, Q., Ma, Y., Wang, F., Tan, X., Song, D., Hoo, R. L. C., Wang, Z., Ge, X., Han, H., et al. (2023) · Pharmacological Research · doi:10.1016/j.phrs.2023.106720 · Cited by 111 · see citing works

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds

Liu, H.-Y., Saxena, A., Sidhu, S., & Wu, D.-H. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.00038 · Cited by 109 · see citing works

Brain Shuttle Antibody for Alzheimer’s Disease with Attenuated Peripheral Effector Function due to an Inverted Binding Mode

Weber, F. C., Bohrmann, B., Niewoehner, J., Fischer, J. A. A., Rueger, P., Tiefenthaler, G., Moelleken, J., Bujotzek, A., Brady, K., Singer, T., et al. (2018) · Cell Reports · doi:10.1016/j.celrep.2017.12.019 · Cited by 105 · see citing works

Endothelial cells are critical regulators of iron transport in a model of the human blood–brain barrier

Chiou, B., Neal, E. H., Bowman, A. B., Lippmann, E. S., Simpson, I. A., & Connor, J. R. (2018) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x18783372 · Cited by 105 · see citing works

Emerging Technologies for Delivery of Biotherapeutics and Gene Therapy Across the Blood–Brain Barrier

Stanimirovic, D. B., Sandhu, J. K., & Costain, W. J. (2018) · BioDrugs · doi:10.1007/s40259-018-0309-y · Cited by 105 · see citing works

Advances and considerations in AD tau-targeted immunotherapy

Bittar, A., Bhatt, N. N., & Kayed, R. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.104707 · Cited by 105 · see citing works

Blood‐brain barrier transport using a high affinity, brain‐selective VNAR antibody targeting transferrin receptor 1

Stocki, P., Szary, J., Rasmussen, C. L. M., Demydchuk, M., Northall, L., Logan, D. B., Gauhar, A., Thei, L., Moos, T., Walsh, F. S., et al. (2020) · The FASEB Journal · doi:10.1096/fj.202001787r · Cited by 101 · see citing works

Heparan sulfate proteoglycan‐mediated dynamin‐dependent transport of neural stem cell exosomes in an in vitro blood–brain barrier model

Joshi, B. S., & Zuhorn, I. (2020) · European Journal of Neuroscience · doi:10.1111/ejn.14974 · Cited by 90 · see citing works

Potential Pathways for CNS Drug Delivery Across the Blood-Cerebrospinal Fluid Barrier

Strazielle, N., & Ghersi‐Egea, J. (2016) · Current Pharmaceutical Design · doi:10.2174/1381612822666160726112115 · Cited by 98 · see citing works

CD98hc is a target for brain delivery of biotherapeutics

Chew, K. S., Wells, R. C., Moshkforoush, A., Chan, D., Lechtenberg, K. J., Tran, H. L., Chow, J., Kim, D. J., Robles‐Colmenares, Y., Srivastava, D. B., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-40681-4 · Cited by 98 · see citing works

The blood–brain barrier: a help and a hindrance

Rust, R., Yin, H. R., Buil, B. A., Sagare, A. P., & Kisler, K. (2025) · Brain · doi:10.1093/brain/awaf068 · Cited by 102 · see citing works

Engineered antibodies: new possibilities for brain PET?

Sehlin, D., & Syvänen, S. (2019) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-019-04426-0 · Cited by 96 · see citing works

Targeted Drug Delivery to the Brain Using Magnetic Nanoparticles

Thomsen, L. B., Thomsen, M. S., & Moos, T. (2015) · Therapeutic Delivery · doi:10.4155/tde.15.56 · Cited by 95 · see citing works

Immunoglobulin Fc Heterodimer Platform Technology: From Design to Applications in Therapeutic Antibodies and Proteins

Ha, J.-H., Kim, J.-E., & Kim, Y. (2016) · Frontiers in Immunology · doi:10.3389/fimmu.2016.00394 · Cited by 92 · see citing works

Endosomal trafficking regulates receptor-mediated transcytosis of antibodies across the blood brain barrier

Haqqani, A. S., Delaney, C. E., Brunette, E., Baumann, E., Farrington, G. K., Sisk, W. P., Eldredge, J. K., Ding, W., Tremblay, T., & Stanimirovic, D. B. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17740031 · Cited by 91 · see citing works

A translational platform PBPK model for antibody disposition in the brain

Chang, H.-Y., Wu, S., Meno‐Tetang, G. M. L., & Shah, D. K. (2019) · Journal of Pharmacokinetics and Pharmacodynamics · doi:10.1007/s10928-019-09641-8 · Cited by 86 · see citing works

Iron metabolism: a double-edged sword in the resistance of glioblastoma to therapies

Legendre, C., & Garcion, E. (2015) · Trends in Endocrinology and Metabolism · doi:10.1016/j.tem.2015.03.008 · Cited by 80 · see citing works

Iron-loaded transferrin (Tf) is detrimental whereas iron-free Tf confers protection against brain ischemia by modifying blood Tf saturation and subsequent neuronal damage

DeGregorio‐Rocasolano, N., Martı́, O., Ponce, J., Castelló‐Ruiz, M., Millán, M., Guirao, V., García‐Yébenes, I., Salom, J. B., Ramos‐Cabrer, P., Alborch, E., et al. (2017) · Redox Biology · doi:10.1016/j.redox.2017.11.026 · Cited by 80 · see citing works

Brain Delivery of Single-Domain Antibodies: A Focus on VHH and VNAR

Pothin, E., Lesuisse, D., & Lafaye, P. J. (2020) · Pharmaceutics · doi:10.3390/pharmaceutics12100937 · Cited by 80 · see citing works

Identification and in vivo characterization of a brain-penetrating nanobody

Wouters, Y., Jaspers, T., Strooper, B. D., & Dewilde, M. (2020) · Fluids and Barriers of the CNS · doi:10.1186/s12987-020-00226-z · Cited by 79 · see citing works

Current progress and limitations of AAV mediated delivery of protein therapeutic genes and the importance of developing quantitative pharmacokinetic/pharmacodynamic (PK/PD) models

Chowdhury, E. A., Meno‐Tetang, G. M. L., Chang, H. Y., Wu, S., Huang, H. W., Jamier, T., Chandran, J. S., & Shah, D. K. (2021) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2021.01.017 · Cited by 78 · see citing works

Brain pharmacokinetics of two BBB penetrating bispecific antibodies of different size

Faresjö, R., Bonvicini, G., Fang, X. T., Aguilar, X., Sehlin, D., & Syvänen, S. (2021) · Fluids and Barriers of the CNS · doi:10.1186/s12987-021-00257-0 · Cited by 76 · see citing works

In vitro models and systems for evaluating the dynamics of drug delivery to the healthy and diseased brain

Modarres, H. P., Janmaleki, M., Novin, M., Saliba, J., Moussa, F. E. H., Charan, M. R., Seyfoori, A., SadAbadi, H., Vandal, M., Nguyen, M. D., et al. (2018) · Journal of Controlled Release · doi:10.1016/j.jconrel.2018.01.024 · Cited by 73 · see citing works

Mechanisms of receptor-mediated transcytosis at the blood-brain barrier

Baghirov, H. (2025) · Journal of Controlled Release · doi:10.1016/j.jconrel.2025.113595 · Cited by 81 · see citing works

Bispecific Antibodies as a Development Platform for New Concepts and Treatment Strategies

Yang, F., Wen, W., & Qin, W. (2016) · International Journal of Molecular Sciences · doi:10.3390/ijms18010048 · Cited by 75 · see citing works

Enhanced Delivery of Galanin Conjugates to the Brain through Bioengineering of the Anti-Transferrin Receptor Antibody OX26

Thom, G., Burrell, M. R., Haqqani, A. S., Yogi, Á., Lessard, E., Brunette, E., Delaney, C. E., Baumann, E., Callaghan, D., Melero, N. R., et al. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00937 · Cited by 74 · see citing works

Phage display derived peptides for Alzheimer's disease therapy and diagnosis

Zhang, X., Zhang, X., Gao, H., & Qing, G. (2022) · Theranostics · doi:10.7150/thno.68636 · Cited by 75 · see citing works

Antibody-Targeted Nanoparticles for Cancer Treatment

Carter, T. J., Mulholland, P. J., & Chester, K. A. (2016) · Immunotherapy · doi:10.2217/imt.16.11 · Cited by 70 · see citing works

Endothelial LRP1 – A Potential Target for the Treatment of Alzheimer’s Disease

Storck, S. E., & Pietrzik, C. U. (2017) · Pharmaceutical Research · doi:10.1007/s11095-017-2267-3 · Cited by 69 · see citing works

Engineering antibody and protein therapeutics to cross the blood–brain barrier

Zhao, P., Zhang, N., & An, Z. (2022) · Antibody Therapeutics · doi:10.1093/abt/tbac028 · Cited by 71 · see citing works

MicroRNA-Based Drugs for Brain Tumors

Anthiya, S., Griveau, A., Loussouarn, C., Baril, P., Garnett, M. C., Issartel, J., & Garcion, E. (2018) · Trends in cancer · doi:10.1016/j.trecan.2017.12.008 · Cited by 71 · see citing works

Single-Domain Antibodies as Therapeutic and Imaging Agents for the Treatment of CNS Diseases

Bélanger, K., Iqbal, U. H., Tanha, J., MacKenzie, R., Moreno, M., & Stanimirovic, D. B. (2019) · Antibodies · doi:10.3390/antib8020027 · Cited by 69 · see citing works

Bispecific antibody shuttles targeting CD98hc mediate efficient and long-lived brain delivery of IgGs

Pornnoppadol, G., Bond, L. G., Lucas, M. J., Zupancic, J. M., Kuo, Y., Zhang, B., Greineder, C. F., & Tessier, P. M. (2023) · Cell chemical biology · doi:10.1016/j.chembiol.2023.09.008 · Cited by 70 · see citing works

Primate-conserved carbonic anhydrase IV and murine-restricted LY6C1 enable blood-brain barrier crossing by engineered viral vectors

(2023) · doi:10.1126/sciadv.adg6618 · Cited by 67 · see citing works

Fc-engineered large molecules targeting blood-brain barrier transferrin receptor and CD98hc have distinct central nervous system and peripheral biodistribution

Khoury, N., Pizzo, M. E., Discenza, C. B., Joy, D. A., Tatarakis, D., Todorov, M. I., Negwer, M., Ha, C., de Melo, G. L., Sarrafha, L., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57108-x · Cited by 73 · see citing works

Active poly‐GA vaccination prevents microglia activation and motor deficits in a C9orf72 mouse model

Zhou, Q., Mareljic, N., Michaelsen, M., Parhizkar, S., Heindl, S., Nuscher, B., Farny, D., Czuppa, M., Schludi, C., Graf, A., et al. (2019) · EMBO Molecular Medicine · doi:10.15252/emmm.201910919 · Cited by 62 · see citing works

Blood-Brain Barrier Transport, Plasma Pharmacokinetics, and Neuropathology Following Chronic Treatment of the Rhesus Monkey with a Brain Penetrating Humanized Monoclonal Antibody Against the Human Transferrin Receptor

Pardridge, W. M., Boado, R. J., Patrick, D. J., Hui, E. K., & Lu, J. Z. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.8b00730 · Cited by 62 · see citing works

Receptor-mediated drug delivery of bispecific therapeutic antibodies through the blood-brain barrier

Pardridge, W. M. (2023) · Frontiers in Drug Delivery · doi:10.3389/fddev.2023.1227816 · Cited by 62 · see citing works

Biomarker-guided decision making in clinical drug development for neurodegenerative disorders

Cummings, J. L., Teunissen, C. E., Fiske, B. K., Ber, I. L., Wildsmith, K. R., Schöll, M., Dunn, B., & Scheltens, P. (2025) · Nature Reviews Drug Discovery · doi:10.1038/s41573-025-01165-w · Cited by 69 · see citing works

In vivo imaging of alpha-synuclein with antibody-based PET

Roshanbin, S., Xiong, M., Hultqvist, G., Söderberg, L., Zachrisson, O., Meier, S. R., Ekmark‐Lewén, S., Bergström, J. J. E., Ingelsson, M., Sehlin, D., et al. (2022) · Neuropharmacology · doi:10.1016/j.neuropharm.2022.108985 · Cited by 60 · see citing works

Transferrin' bispecific antibodies across the blood–brain barrier

Bray, N. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4522 · Cited by 16 · see citing works

Boosting Brain Uptake of a Therapeutic Antibody by Reducing Its Affinity for a Transcytosis Target

Yu, Y. J., Zhang, Y., Kenrick, M., Hoyte, K., Luk, W., Lu, Y., Atwal, J., Elliott, J. M., Prabhu, S., Watts, R. J., et al. (2011) · Science Translational Medicine · doi:10.1126/scitranslmed.3002230 · Cited by 794 · see citing works

Novel Human/Non-Human Primate Cross-Reactive Anti-Transferrin Receptor Nanobodies for Brain Delivery of Biologics

Rué, L., Jaspers, T., Degors, I. M. S., Noppen, S., Schols, D., Strooper, B. D., & Dewilde, M. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15061748 · Cited by 29 · see citing works

O1‐06‐02: Enhancing antibody uptake in brain to target BACE1

Atwal, J., Yu, J., Zhang, Y., Chen, Y., Chiu, C., Meilandt, W. J., Scearce-Levie, K. A., Lu, Y., Kenrick, M., Prabhu, S., et al. (2012) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.05.234

Transferrin receptor (TfR) trafficking determines brain uptake of TfR antibody affinity variants

Bien‐Ly, N., Yu, Y. J., Bumbaca, D., Elstrott, J., Boswell, C. A., Zhang, Y., Luk, W., Lu, Y., Dennis, M. S., Weimer, R. M., et al. (2014) · The Journal of Experimental Medicine · doi:10.1084/jem.20131660 · Cited by 350 · see citing works